European Union @ United Nations, Partnership in Action
 
 
EU-related events in and around New York City: learn more about academic programs and think-tank events, arts festivals and cultural activities.

 
EU in the USA - delegation to Washington, DC

< Back to previous page

Commissioner Byrne's Speech on Health equals Wealth

Summary: October 3, 2003: David BYRNE, European Commissioner for Health and Consumer Protection on "Health equals Wealth" at the European Health Forum (Bad Gastein)

Minister Waneck, Dr. Leiner, Ladies and Gentlemen,

The crisp clean air of the Gastein Health Forum, is always a pleasure after the Brussels hothouse! I would like to thank our hosts Dr. Gunter Leiner and his unique team for their welcome and their professionalism in making this event a reality. Because the Gastein Health Forum remains one of the most important events on the European Health calendar.

Over the years here, I have used this unique setting to take soundings with the health policy community on the future direction of health-related policy at European level. In the past I have spoken about the public health agenda, the challenge of enlargement, and the need to develop a "Europe of Health".

On all of these fronts, remarkable progress is being made. The new, 6-year public health programme, is up and running. Before too long, we will begin to see a comprehensive health knowledge and information system take shape. Led by the EU, a ground-breaking global agreement on public health has been agreed - the Framework Convention on Tobacco Control.

This is the first international health agreement of its kind. But not, I hope, the last.

Before the summer break, the Commission adopted our important proposal to have a European Centre for Disease Prevention and Control up and running in 2005. Public health's institutional landscape is changing to deal with new European realities.

Several other major networks and structures are under development, such as the EU Health Forum and the health portal. At a high level our ministers and stakeholders are examining the best way forward for patients, professionals and health systems.

As committed advocates of this "Europe of health", I would like to thank my services and you the wider community of health advocates, for helping to make this happen.

Because looking back at the last four years, I can safely say one thing. We don't come here just to look at the mountains, we come here to move them!

So what is the next health summit to be scaled? Which is the next policy mountain? Having spent more than a year working to bring home the centrality of health to any meaningful definition of European citizenship in the new Treaty, I have a few mapping suggestions.

I have been struck by the fact that while we are winning the political argument on health at European level, we have only begun to address the economic case. And in the end, in government, it is the economic case which is definitive.

For finance ministers, the word's "health", "spending" and "bottomless pit" tend to go together. Therefore, if we are to win the argument for greater European co-operation on the protection and promotion of health, we must speak to Finance Ministers on their terms and in their own language.

They must be convinced that intelligent investment in health, increases financial choice and feeds economic productivity. To do this, the argument about health needs to be turned on its head.

In summary, we must begin to ask simply not what economists can do for health, but what health can do for the economy.

Health and Economic Prosperity

Our wealth is predicated on our health. Modern economic prosperity could not have developed so quickly, without what one writer calls "a culture of pills and soap". In a knowledge-driven society, to add economic value, you must first add years of healthy living.

In an ageing Europe, a healthy active workforce will be a key determinant of sustainable productivity. For the EU's Lisbon Agenda to work, a healthy society will be a key condition.

Yet in political terms the broad subject of health is all too often seen in a negative light. Health as an "overhead". Health as a "drain" on public finances. Health always calculated as a cost, never as a benefit. Health as current expenditure, never as long-term human capital investment.

We need to fundamentally challenge this thinking. Because it is selective, short-termist, unproductive thinking. We know that good short-term financial tactics, can sometimes mean bad long term economic strategy.

Of course, the challenge is to separate out genuine self-financing investment in health, from the escalating current expenditure which needs to be carefully managed if our social model is to remain sustainable.

We need to encourage a counter-current in health economics thinking. A new perspective on health as a productive force in economic prosperity needs to take hold in Europe. Based on agreed methodologies and hard data, this new perspective should confirm a few key messages.

That health is a limited, fragile and invaluable resource.

That well-managed health systems are positive, forward looking investments.

That health is a productive economic factor in terms of employment, innovation and economic growth.

That significant reductions in avoidable and costly ill-health, can be achieved with relatively modest investments.

That effective health promotion and disease prevention can eventually improve the options available within tight budgets.

That the health of our politics, will depend on managing the politics of health. For our European citizens, access to affordable high-quality healthcare, is one of the benchmarks of successful modern governance.

That in many ways, the long term health of the European economy, will depend on the health and longevity of its citizens.

The message is clear. Health is a driver of economic prosperity. Or to summarise it.

Health equals wealth.

The Economics of Positive Health

Professor Sach's work for the WHO Commission on Macroeconomics and Health, confirmed that increasing life expectancy, increases the economic growth rate.

He also revealed that as much as half of the growth differential between rich and poor countries is due to ill-health and demography.

So just how does investing in health and healthcare help economic performance? Allow me to give just a few examples.

The case of SARS has conclusively demonstrated the economic value of effective public health measures. The economic costs of pandemics are measured not in millions, but in percentages of GDP.

Secondly, the indirect costs of ill-health - such as productivity - are very high. One recent study has calculated the lifetime costs of cardio-vascular disease to Germany. Direct health costs are estimated at 25 billion dollars. The indirect costs in productivity are nearly double, at 48 billion dollars!

And this is just the projected cost of one, largely avoidable, existing condition. But there are new health challenges for the population.

In Finland, 40% of new disability pensions are now for mental health reasons.

Looking to the US, we can see the approaching tide of ill-health. In a country half the size of the enlarged EU, one study estimates that the direct and indirect cost of obesity, diabetes and tobacco, each top the 100 billion dollar mark annually. According to another survey, mental ill-health already accounts for 2.5% of GNP in the US.

In the Europe of 25, between 5-10% of GDP is spent on health. Healthcare is a leading source of new employment. It already accounts for around 10% of employment.

If ill-health will continue to affect economic prosperity on this scale, then improving the population's health must be an economic priority. The health of the population will continue to set the economy's metabolic rate. You could say that in the longterm, No pain, means gain!

Wise investment in health, as in education or infrastructure, is investment in the productive capacity of the economy.

Clearly, the issue of effective investment in health systems preoccupies our governments. But in a world of brilliant technological innovations and rising treatment costs, greater efforts are needed to reduce the avoidable disease burden. Effective prevention and promotion can ease the pressure on treatment.

We already have data from the US, that every dollar invested in physical activity leads to medical cost savings of 3 dollars.

With inactivity contributing 75 billion dollars to the US health bill, investment in physical activity looks cheap at the price.

In another project at Stanford, the effect of basic multi-risk programmes are clear. Under one scenario, for every 5 dollars annual per capita investment in education and prevention on blood pressure, smoking and cholesterol - the US economy would save 16 billion dollars of direct costs over a 25 year period.

In addition, there would be indirect benefits to the economy and to society. And by the way, 16 million added life years!

In citing these examples, I hope that you will have been as struck as I am on the absence of equivalent data for the EU as a whole. If we are to be serious about economic growth in the EU, then we must prioritise the systematic gathering of data, to facilitate difficult policy choices. The information strand of the new public health programme will provide a first step in this direction.

I would like to have a more complete picture of EU health, based on a handful of indicators. These indicators should measure:

Indicators such as the healthy life expectancy; infant mortality rate; smoking prevalence; suicide rates; and antimicrobial resistance rates, would paint a rough picture for us. We could look at the emerging picture with health and economic ministers at regular intervals.

Looking at the roll-call of premature and avoidable ill-health, the economic impact of effective prevention and promotion is evident.

Cardiovascular disease, cancer, obesity, musculo-skeletal disease, accidents and injuries, diabetes, sexually transmitted diseases, mental ill-health. All are reducible costs to individuals, society and the economy.

Selecting the appropriate mix of prevention and promotion tools will require clear economic analysis. More substantial investments such as education, information campaigns and population screening are effective. But legislation on issues such as tobacco control, and more effective enforcement of existing alcohol policies, can produce results with little or no cost.

On the other hand, no finance minister will object to another available instrument - higher taxes on tobacco.

To win the economic argument for health, we must develop the EU knowledge base. The WHO has provided solid evidence for the developing and middle-income countries.

As a future priority, I believe that we need to gain a better picture of how these economic pathways operate in the EU.

Of course, at EU level, we have neither the legal competence nor the headache of health management. Because of this, I believe that we can facilitate an evidence-based reflection on the longer term economics of health with our Member States.

At European level I believe that we can bring significant additional value to this debate. We can share experiences and develop more accurate analysis.

We can work to quantify the comparative economic benefits of prevention and promotion measures whether behavioural, legislative or technological, using data from across the EU.

We could support the Member States by developing new indicators and methodologies to set out the relative economic benefits of different policy choices. To name but a few:

What are the economic pros and cons of behaviour-based approaches on diet or physical activity?

What is the long term economic impact of legislation at national or EU level on issues like tobacco control?

How can we assess the economic cost/benefit of different secondary prevention approaches such as population screening?

In the long term, other issues will need to be addressed by those who run and fund the health systems. What are the most efficient ways of maximising choice in setting priorities to deal with the needs of a longer-working ageing population, in everything from prevention to pharmaceutical research?

But to support this unfolding debate amongst the Member States, we will need to work together to make the scientific data available. We need to develop better indicators and methodologies. We need to be better informed of the true value of the measures we employ.

At Community level, there are already some signs of progress.

With our colleagues in Social Protection, we are already engaged in the process of assessing the social and economic impact of ageing on healthcare provision.

I am pleased that the High Level Process on Patient Mobility is beginning to address a number of these issues. Given the impact of technology on rising healthcare budgets, its work on the wider use of Health Technology Assessment will be helpful. With greater co-operation we can avoid duplication of effort and make savings.

There are many other areas of European co-operation on health which could have significant economic benefits. Practical co-operation between regions, centres of excellence and providers could lower some costs.

Making better information available to patients and professionals will improve decision-making. More progress on rational prescribing and more efficient pharmaceutical policy will have a critical effect on supply and demand costs.

We also need more effective public health decisions.

The public health programme has a general goal to strengthen our capacity to assess and evaluate health strategies and interventions.

And we need to use economic analysis to anchor health concerns in other european policies. Economic analysis will be an essential lever in moving the health agenda forward within European policymaking.

The challenge of enlargement

The need to invest in health to ensure economic development is most evident in the health divide arising within an enlarged EU.

Where previously we have measured the social cohesion gap in terms of purchasing power, we will now be able to measure it in terms of life expectancy and infant mortality rates.

The burden of ill-health on the economies of the acceding states will reflect on the overall economic performance of the entire enlarged European Union.

This can be tackled by making full use of the EU Structural Funds and other instruments.

But our new Member States must request it, in their programming design. We can and must finance the investment in health as a driver of economic development.

We cannot tolerate a situation in Europe, where geography would effectively become a health determinant. The original purpose of the enlargement process was to rewrite history. Now we can see that for our new citizens, we must also act to transform the accidents of geography.

In the enlargement debate, we hear a lot about convergence criteria. Well, in the unfolding debates on Financial, economic and political perspectives, I will insist on a new convergence criterion. Health.

Every spring, when the EU meets to measure economic and social progress, we must measure economic development using suitable health indicators. There must be a clear commitment to measure the progress of our Member States in improving their health status and in closing the health gap.

We cannot seriously discuss economic convergence, without looking at the gap in life expectancy of between 5 and 10 years, between those at the top and those at the bottom of the social scale. We need new indicators for a new Europe.

I believe that the next generation of European citizens should have a new health birthright. Their new European birthright should ensure equal access to a longer, healthier and more productive life. It should be a defining legacy of their European citizenship.

The Commission can and will support this process of re-defining the economics of health and the health of economics. We will take forward new high profile case studies under the public health programme.

We will review the use of the EU structural funds and other instruments to ensure that they address health needs in the most productive manner. In our forthcoming Health Policy Communication, we will propose to develop a "health economics framework" for the European Union. A coherent approach to bring together health, social and economic policies and actors.

We must take action to give health a central place on the EU's economic and social agenda. Large reductions in mortality and morbidity can be achieved almost everywhere.

Well-targeted measures, using existing and new technologies, could save a huge number of lives and generate yearly economic benefits. The forthcoming decades will see the potential for everyone to live longer, more productive lives than ever before.

But of course, we need to ensure that our actions will add life to those years, not only years to life.

Thank you.


  • Ref: SP03-263EN
  • EU source: European Commission
  • UN forum: 
  • Date: 3/10/2003


< Back to previous page

 

European Union Member States